ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TELA vs NEPH // EV/EBITDA & P/E VALUATION

TELA Bio Inc. (NASDAQ) VS. Nephros Inc. (NASDAQ) • 15-METRIC TALLY: TELA 2 — NEPH 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TELA VS. NEPH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TELA NEPH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 67.70% 61.90% +5.80 TELA /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 18.90% -53.90 NEPH /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 26.3x — TIE /valuation <GO>
Free Cash Flow Yield — 4.50% — TIE /fcf-yield <GO>
Operating Margin -42.00% 6.10% -48.10 NEPH /operating-margins <GO>
Net Profit Margin -48.30% 6.40% -54.70 NEPH /net-margins <GO>
Revenue Growth (YoY) 15.80% 32.70% -16.90 NEPH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 NEPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.8 36.7 -2.90 NEPH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 25.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $41.5M $35.5M $6.0M TELA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TELA REV NEPH REV TELA GROSS % NEPH GROSS % TELA FCF NEPH FCF
FY 2025 $80.3M $18.8M 67.7% 61.9% -$28.7M $1.6M
FY 2024 $69.3M $14.2M 67.1% 61.6% -$42.6M -$547.0K
FY 2023 $58.5M $14.2M — — -$40.9M $827.0K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TELA // BETA —
NEPH // BETA —